Bone mineral density in patients with thalassemia major, the experience of a single institute

Ahmed I Ansaf (1) , Safa A Faraj (2) , Rahan A Mohammed (3)
(1) Department of Pediatrics, College of Medicine, Wasit University, Kut, Iraq, Iraq ,
(2) Department of Pediatrics, College of Medicine, Wasit University, Kut, Iraq, Iraq ,
(3) Department of Pediatrics, Shakhan general hospital, Mousel, Iraq, Iraq

Abstract

Thalassemia is an inherited disorder causing an imbalance in the development of the globin chain with ineffective erythropoiesis and increased peripheral consumption. Expansion of bone marrow decreases bone mineral density. Bone disease in thalassemia is manifested as diffuse bone pain, scoliosis, spinal deformities, nerve compression, spontaneous fracture. Bone Mineral Density (BMD) is a useful indicator for bone monitoring and assessment and significant predictor of bone disease in thalassemia. The purpose of this study is to evaluate Bone Mineral Density in thalassemia patients and its correlation with other factors. The study was conducted in Hematology Center at Al-Karama Teaching Hospital, Wasit, Iraq, from the first of January to the thirty of April 2019. Fifty-eight thalassemia patients were enrolled in this study. Bone mineral density was assessed using Dual-Energy X-ray Absorptiometry technique (DEXA scan) for the lumber spine (L1-L4) at the Dexa unit in the rehabilitation Center in KUT. The patients were divided according to BMD by Z-Score ≤ 15 years old patients, T score for adults (>15 years old) into three groups: a score ≥ -1 defined as Normal BMD, Osteopenia (between -1 and -2.5 SD), and  Osteoporosis (below -2.5 SD). The effect of Gender, Age, frequency of blood transfusion, Hb level, Serum Calcium, and Serum Ferritin on BMD was evaluated. Young patients (with age equal to or younger than 15 years) showed lower bone density than older patients. Also, Patients with Suboptimal blood transfusion had lower bone density than patients than good compliance blood transfusion program, P-value 0.001, 0.012, respectively. The results indicated a direct relationship between the age of the thalassemia patients and bone mass density, P-value = 0.0001, Pearson Correlation = 0.7. Low bone density was reported in young age and suboptimal blood transfusion.

Full text article

Generated from XML file

References

Anapllotou, M. L. G., et al. 1995. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clinical Endocrinology, 42(3):279– 287.

Aslan, I., et al. 2012. Bone Mineral Density in Thalassemia Major Patients from Antalya, Turkey. International Journal of Endocrinology, 2012:1–4.

Borgna-Pignatti, C. 2006. Thalassemia. A few new tiles in a large mosaic. haematologica, 91(9):1159–1161.

Ishaq, F., et al. 2015. Frequency of Low Bone Mineral Density and Osteoporosis in Children with Beta Thalassemia Major. Pakistan Journal Of Medical & Health Sciences, 9(3):1073–1076.

Jensen, C. E. 1998. High prevalence of low bone mass in thalassaemia major. British Journal of Haematology, 103(4):911–915.

Leung, T. F., et al. 2005. Bone mineral density in children with thalassaemia major: determining factors and effects of bone marrow transplantation. Bone Marrow Transplantation, 36(4):331–336.

Molyvda-Athanasopoulou, E., et al. 1999. Bone Mineral Density of Patients with Thalassemia Major: Four-Year Follow-Up. Calcified Tissue International, 64(6):481–484.

Morabito, N., et al. 2002. Bisphosphonates in the Treatment of Thalassemia-Induced Osteoporosis. Osteoporosis International, 13(8):644–649.

Nesheli, H. M., Farahanian, E. 2016. Relation between bone mineral density and serum ferritin levels in patients with thalassemia major. Caspian Journal of Pediatrics, 2(2):158–163.

Olivieri, N. F., Brittenham, G. M. 1997. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood, 89(3):739–761.

Orvieto, R., et al. 1992. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcified Tissue International, 50(5):397–399.

Pootrakul, P. 1981. Relation between erythropoiesis and bone metabolism in thalassemia. Journal of Pediatric Orthopaedics, 1(4):457.

Rafsanjani, K. A., et al. 2009. Bone mineral density in beta-thalassemia major and intermedia, correlation with biochemical and hormonal profiles. Iranian Journal Of Blood And Cancer (IJBC), 1(4):121–127.

Shamshirsaz, A. A., et al. 2007. Bone mineral density in iranian adolescents and young adults with β-thalassemia major. Pediatric Hematology and Oncology, 24(7):469–479.

Singh, J. A., et al. 2012. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research, 64(5):625–639.

Voskaridou, E., et al. 2001. Bone resorption is increased in young adults with thalassaemia major. British Journal of Haematology, 112(1):36– 41.

Voskaridou, E., Terpos, E. 2004. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. British Journal of Haematology, 127(2):127–139.

Wonke 1998. Bone disease in β-thalassaemia major. British Journal of Haematology, 103(4):897–901.

Authors

Ahmed I Ansaf
Safa A Faraj
Safaafaraj@uowasit.edu.iq (Primary Contact)
Rahan A Mohammed
Ahmed I Ansaf, Safa A Faraj, & Rahan A Mohammed. (2021). Bone mineral density in patients with thalassemia major, the experience of a single institute. International Journal of Research in Pharmaceutical Sciences, 12(1), 676–682. Retrieved from https://ijrps.com/home/article/view/329

Article Details

No Related Submission Found